Cocrystal Pharma, Inc. (COCP) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-02-25

Key Insights

Phillip Frost, a 10% owner and director of Cocrystal Pharma, Inc. (COCP), purchased 20,000 shares of the company's common stock at an average price of $0.9976 per share, indicating confidence in the company's prospects.
The shares purchased by Frost were held indirectly through Frost Gamma Investments Trust, which now holds a total of 1,908,551 shares of COCP, representing a significant ownership stake.
Frost's insider buying activity, combined with his existing substantial ownership position, suggests he believes the company's stock is undervalued and presents an attractive investment opportunity.

Want the newest filings?

This analysis covers the filing from 2026-02-25. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-09

Dr. Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), acquired an additional 50,000 shares of the company's common stock on February 6, 2026 at an average price of $0.9456 per share.
Dr. Frost's total beneficial ownership in COCP increased to 1,888,551 shares, indicating his strong conviction in the company's prospects.
The filing also shows that Dr. Frost holds shares indirectly through Frost Gamma Investments Trust, suggesting a long-term investment strategy in the company.

Filed: 2026-01-13

Richard C. Pfenniger Jr., a director of Cocrystal Pharma, Inc. (COCP), has been granted 16,410 non-qualified stock options with a 10-year term and an exercise price of $1.10 per share.
The options will vest in two equal tranches, with the first half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, subject to Pfenniger's continued service as a director.
This grant of options aligns Pfenniger's interests with those of COCP shareholders and incentivizes him to contribute to the company's long-term success.

Filed: 2026-01-13

The reporting person, Roger D. Kornberg, was granted 24,615 non-qualified stock options by Cocrystal Pharma, Inc. (COCP) on January 9, 2026, with a 10-year term and an exercise price of $1.10 per share.
The stock options will vest in two tranches, with 50% vesting on January 9, 2027 and the remaining 50% vesting in 8 equal quarterly installments starting March 31, 2027, contingent on Kornberg's continued service as a director.
This stock option grant suggests that Cocrystal Pharma is incentivizing and retaining its board members, which could signal confidence in the company's long-term prospects.

Filed: 2026-01-13

Insider Sam Lee, President and Co-CEO, acquired 49,229 stock options in Cocrystal Pharma, Inc. (COCP) on January 9, 2026, potentially indicating his confidence in the company's future performance.
The stock options granted to Lee have a 10-year term and will vest over time, aligning his interests with those of other shareholders.
The transaction was reported on a timely basis, suggesting transparent communication with investors about insider trading activities.

Filed: 2026-01-13

Fred Hassan, a director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options on January 9, 2026, vesting over two years.
The stock options have an exercise price of $1.1 per share and are exercisable until January 9, 2036.
This insider grant suggests the director's confidence in the company's future prospects and alignment with shareholder interests.

Filed: 2026-01-13

The reporting person, James Martin, has been granted 49,229 stock options with an exercise price of $1.1 and a 10-year expiration, as part of the company's 2025 Equity Incentive Plan.
The options will vest in two tranches, with half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting March 31, 2027, subject to his continued service as an officer.
This stock option grant suggests the company is incentivizing the Co-CEO and CFO to remain with the organization and drive long-term value creation.

Filed: 2026-01-13

Dr. Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), was granted 24,615 non-qualified stock options on January 9, 2026 under the company's 2025 Equity Incentive Plan.
The stock options have a 10-year term and will vest in two installments, with half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting March 31, 2027.
Dr. Frost's ownership of COCP stock options provides alignment with other shareholders and incentivizes him to continue serving on the company's board of directors.

Filed: 2026-01-13

Anthony J. Japour, a director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options on January 9, 2026 with a 10-year expiration and exercise price of $1.1 per share.
The stock options will vest in two tranches: 50% on January 9, 2027 and the remaining 50% in eight equal quarterly installments starting on March 31, 2027, subject to Japour's continued service as a director.
This grant of stock options to a director is a common form of equity compensation to align the interests of the board with shareholders.

Filed: 2026-01-13

The reporting person, Steven Rubin, has been granted 16,410 non-qualified stock options by Cocrystal Pharma, Inc. (COCP) under the company's 2025 Equity Incentive Plan.
The stock options have a 10-year term and will vest in two equal installments, with half vesting on January 9, 2027 and the remaining half vesting in eight quarterly installments starting on March 31, 2027, subject to Rubin's continued service as a director.
This stock option grant aligns the interests of the reporting person, who is a director of COCP, with those of the company and its shareholders, as it provides an incentive for Rubin to contribute to the company's long-term success.

Filed: 2026-01-02

Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), purchased 50,000 shares of the company's common stock on December 31, 2025 at an average price of $0.9455 per share.
Frost Gamma Investments Trust, of which Phillip Frost is the trustee, owns a significant stake of 1,838,551 shares in COCP, indicating Frost's continued confidence in the company.
The Form 4 filing also discloses that Frost has disposed of 27,100 shares, likely for portfolio rebalancing or liquidity purposes.

Filed: 2025-12-31

Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), purchased an additional 20,000 shares of common stock on December 30, 2025 at a weighted average price of $0.9655 per share.
Frost Gamma Investments Trust, which is controlled by Phillip Frost, holds a significant indirect beneficial ownership stake of 1,788,551 shares in COCP.
The Form 4 filing does not include any securities owned directly by OPKO Health, Inc., a company where Phillip Frost is the Chairman and CEO, as he disclaims beneficial ownership of those shares.

Filed: 2025-12-29

Insider Phillip Frost, MD ET AL, reported purchasing a total of 65,000 shares of Cocrystal Pharma, Inc. (COCP) on December 24 and 26, 2025, increasing his indirect beneficial ownership to 1,768,551 shares.
The reported purchases were made at weighted average prices of $0.9703 and $0.9736 per share, suggesting Dr. Frost believes the stock is undervalued at current levels.
The filing indicates Dr. Frost holds his COCP shares through Frost Gamma Investments Trust, of which he is the trustee, suggesting he maintains a long-term investment strategy in the company.

Other reports for Cocrystal Pharma, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.